Higher baseline serum magnesium levels are linked to a higher risk for cardiac events in HFmrEF/HFpEF, while empagliflozin treatment shows a lower risk for these events in those with higher magnesium.

USA: In a post hoc analysis of the ADJUST-T1D trial, adults with type 1 diabetes receiving once-weekly semaglutide 1 mg showed a significant reduction in total daily insulin dose by 4 weeks, ...

62.7% relative reduction in mortality at day 30, which persisted through day 60, for patients treated with Auxora versus placebo in subset of patients in CARDEA with AKI The new data presented were ...

SEOUL, South Korea, Aug. 12, 2025 /PRNewswire/ -- A newly published post-hoc analysis of the landmark FUEL (Fontan Udenafil Exercise Longitudinal) Trial demonstrates that udenafil, a PDE5 inhibitor, ...

As previously disclosed, the studies did not meet pre-specified co-primary, secondary, or exploratory biomarker endpoints The paper provides a detailed analysis of the RETHINK-ALZ and REFOCUS-ALZ ...

SAN DIEGO, Sept. 21, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) (Nasdaq: NBIX), today announced that it will present a new post hoc analysis of Phase 2 data of the investigational drug ...

MILAN, Italy — The antisense oligonucleotide vupanorsen substantially reduces very low density lipoprotein (VLDL) and remnant cholesterol levels in patients with raised lipids despite statin therapy, ...

In a post-hoc analysis of the DELIVER trial, interictal periods were longer with VYEPTI compared to placebo and corresponded to higher patient-reported quality of life outcomes Individuals taking ...

THE WOODLANDS, Texas, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that data from four studies of sotagliflozin will be delivered during the American ...